Martin R. Farlow

Research interests

Publications

• Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02476-4

• Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid

  Nature · 2022 · https://doi.org/10.1038/s41586-022-05397-3

• A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01369-8

• A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0781-z

• Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-019-14279-8

• Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD

  Acta Neuropathologica · 2019 · https://doi.org/10.1007/s00401-019-01962-9

• The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease

  Brain · 2018 · https://doi.org/10.1093/brain/awy132

• Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

  Neurology · 2018 · https://doi.org/10.1212/wnl.0000000000006277

• Transethnic genome‐wide scan identifies novel Alzheimer's disease loci

  Alzheimer s & Dementia · 2017 · https://doi.org/10.1016/j.jalz.2016.12.012

• Assessment of the genetic variance of late-onset Alzheimer's disease

  Neurobiology of Aging · 2016 · https://doi.org/10.1016/j.neurobiolaging.2016.02.024

• Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

  Alzheimer s Research & Therapy · 2015 · https://doi.org/10.1186/s13195-015-0108-3

• Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy

  Nature Communications · 2015 · https://doi.org/10.1038/ncomms8247

• Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease

  JAMA Neurology · 2014 · https://doi.org/10.1001/jamaneurol.2014.1491

• Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1312889

• A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1210951

• Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

  Nature Genetics · 2011 · 10.1038/ng.801

Current projects

No projects listed.